This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenblum, M. L. Articles by Wilson, C. B. Search for Related Content PubMed PubMed Citation Articles by Rosenblum, M. L. Articles by Wilson, C. B.

In Vivo Clonogenic Tumor Cell Kinetics following 1,3-Bis(2-chloroethyl)-1-Nitrosourea Brain Tumor Therapy¹

The Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, California 94143

An in vitro colony formation assay was modified to determine the effects of in vivo 1,3-bis(2-chloroethyl)-1-nitrosourea therapy on tumor cell kill and subsequent clonogenic cell kinetics. The measured surviving fraction must be multiplied by the relative total number of tumor cells for each posttreatment interval in order to eliminate inaccuracies caused by dead cell removal in vivo and the lysis of damaged cells by the disaggregation procedure. The assumptions, limitations, and applications of the technique are discussed.

1,3-Bis(2-chloroethyl)-1-nitrosourea doses of 0.25, 0.50, and 1.00 x dose lethal to 10% of animals resulted in approximately a 1-, 2-, and 3-log cell kill, respectively. Significant proliferation of surviving clonogenic cells was observed after a latency period of approximately 2 days, and the rate of tumor regrowth was dose dependent. The cell-doubling times following treatment with 0.25, 0.50, and 1.00 x doses lethal to 10% of animals were 15, 21, and 38 hr, respectively. The interval to complete repopulation of the clonogenic pool corresponds to the observed increase in animal lifespan for the 2 larger doses and further validates the assay as a true measure of in vivo chemotherapeutic efficacy.

¹ This work was supported by NIH Grant CA-13525, The National Phi Beta Psi Sorority, The Joe Gheen Medical Foundation, and the Association for Brain Tumor Research.

² Recipient of American Cancer Society Clinical Fellowship CF-3537. To whom requests for reprints should be addressed.

Received 4/ 2/76. Accepted 6/30/76.

This article has been cited by other articles:

				D. De Ruysscher, M. Pijls-Johannesma, S. M. Bentzen, A. Minken, R. Wanders, L. Lutgens, M. Hochstenbag, L. Boersma, B. Wouters, G. Lammering, et al. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1057 - 1063. [Abstract] [Full Text] [PDF]

				L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]

				I. F. Tannock Limited Drug Access and Repopulation of Surviving Tumor Cells between Courses of Chemotherapy: Important and Neglected Causes of Clinical Drug Resistance Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 103 - 107. [Full Text] [PDF]

				W. Licun and I. F. Tannock Selective Estrogen Receptor Modulators as Inhibitors of Repopulation of Human Breast Cancer Cell Lines after Chemotherapy Clin. Cancer Res., October 1, 2003; 9(12): 4614 - 4618. [Abstract] [Full Text] [PDF]

				L. Wu and I. F Tannock Repopulation in Murine Breast Tumors during and after Sequential Treatments with Cyclophosphamide and 5-Fluorouracil Cancer Res., May 1, 2003; 63(9): 2134 - 2138. [Abstract] [Full Text] [PDF]

				B. D. Ross, Y.-J. Zhao, E. R. Neal, L. D. Stegman, M. Ercolani, O. Ben-Yoseph, and T. L. Chenevert Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: An MRI study PNAS, June 9, 1998; 95(12): 7012 - 7017. [Abstract] [Full Text] [PDF]